#United States #Wilmington #weight loss #Akkermansia muciniphila #MucT

New Clinical Study on Akkermansia Muciniphila

Akkermansia muciniphila MucT, a proprietary bacterial strain, has shown promising results in maintaining weight loss according to a newly published clinical trial in Nature Medicine. Conducted by The Akkermansia Company, the randomized, placebo-controlled trial involved 90 participants who were initially put on a low-energy diet for eight weeks to achieve a minimum 8% weight loss. Following that period, participants entered a 24-week maintenance phase during which half received the MucT supplement daily, while the other half were given a placebo alongside a non-restricted diet.

The results were striking: participants taking MucT regained only 1.2 kg on average during the maintenance period, while those on the placebo regained an average of 3.2 kg (P=0.012). Notably, about 40% of those in the MucT group continued to lose weight during this period, compared to just 5% in the placebo group. Importantly, no side effects related to the MucT supplement were reported, indicating its safety for participants.

Professor Willem M. de Vos, co-founder of The Akkermansia Company, emphasized the importance of these findings. He stated, "Long-term weight maintenance remains one of the greatest unmet challenges in obesity management." This research not only underscores the efficacy of Akkermansia muciniphila MucT in weight management but also enhances understanding of its role in promoting metabolic health.

In addition to weight control, the study revealed that participants using MucT maintained better insulin sensitivity as well. Analysis of their adipose tissue showed increased activity in pathways related to energy metabolism and reduced inflammatory signals, suggesting that MucT might help create a more metabolically active and less inflammatory state within the body. These positive changes could be essential in combating the biological mechanisms that often lead to weight regain after dieting.

The trial, which is registered on ClinicalTrials.gov (NCT05417360), was conducted in collaboration with esteemed institutions such as Maastricht University Medical Center+, the University of Copenhagen, and Wageningen University Research. Funding for the study was provided by The Akkermansia Company, reflecting its commitment to advancing scientific knowledge about gut microbiome solutions for better metabolic health.

Since its launch in the Belgian market in 2021, Akkermansia muciniphila MucT has expanded its presence across Europe, North America, and Asia, bringing innovative solutions to those seeking support in weight loss and metabolic health maintenance. The company is dedicated to developing science-based strategies to tackle the obesity epidemic, which continues to pose significant challenges globally.

For more details about the study and the company's products, you can visit their official website at The Akkermansia Company.

Disclaimer: These statements have not been evaluated by the FDA, and this product is not intended to diagnose, treat, cure, or prevent any disease.